Published in Biotech Law Weekly, January 13th, 2006
SansRosa is the assignee of various patent applications covering methods for the treatment of redness associated with rosacea and other skin disorders.
Payment for shares of SansRosa will be made in installments tied to the achievement of various product development milestones. CollaGenex will be solely responsible for product and clinical development.
CollaGenex will make an initial payment of $750,000 for 51% of the shares of SansRosa. The remaining shares will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.